Ambrisentan

BNF:
2.5.1
Status:
Red
Decision Date:
None
 

Comments

Treatment of pulmonary arterial hypertension in adults, adolescents and children (aged ≥8 to <18 years) of WHO Functional Class II to III, including use in combination treatment [new 2.5mg tablet formulation].

NHS England commissioned.  To be used in line with NHSE commissioning intentions.

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app